Press "Enter" to skip to content

Merck Seeks FDA Approval for Antiviral Pill for Covid-19

Merck & Co. and Ridgeback Biotherapeutics filed an emergency use authorization request with the Food and Medication Administration on Monday for molnupiravir. This antiviral drug has the potential to treat COVID-19 with a tablet shortly. According to the firms, molnupiravir, an orally swallowed antiviral tablet, is used to treat mild to moderate adult instances of COVID-19 that are at risk of progressing to severe COVID-19 or requiring hospitalization.

It was developed by Emory University researchers in Atlanta and is administered as four pills twice a day for five days. According to an interim analysis of a clinical trial, the antiviral medication lowered the chance of hospitalization or death by about 50%. As a result, public health officials have hoped for efficient antivirals to help avoid severe infection in persons who have been exposed to the SARS-CoV-2 virus since the beginning of the pandemic.

Early on, several existing medications were tested against the virus, but none of them were found to be beneficial to patients. In June, the Biden administration announced a $3.2 billion investment in antiviral research, claiming that the treatments would be critical in the fight against the virus. Merck said it would spend roughly 1.7 million doses of molnupiravir to the US government for distribution if the treatment wins emergency use authorization. Texas Governor Greg Abbott, a vocal opponent of vaccine and mask mandates, went even further on Monday, issuing an executive order prohibiting the state from requiring vaccines.

The order prohibits any organization from forcing vaccination of state residents, including employees and consumers, who oppose for reasons of personal conscience, religious belief, or medical need, including prior recovery from COVID-19. Abbott also requested that the restriction be added to the Texas legislature’s Third Special Session agenda so that it could be reviewed and passed.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *